Faculty

Back to Index
Harvey R Kaslow, PhD
Associate Professor of Physiology & Biophysics
Zilkha Neurogenetic Institute
MCH 250, 1333 San Pablo Street Health Sciences Campus Los Angeles
+1 323 442 1244

Overview

Recommended URLs:
http://profiles.sc-ctsi.org/harvey.kaslow
http://www-hsc.usc.edu/~hrkaslow/

Main research interest: Cancer Immunotherapy and Regulation of Immune Responses.
Cytotoxic antibodies and T lymphocytes can be generated that recognize cancer cells, but immunosuppressive factors in solid tumors frequently cause these effectors to fail to control or eliminate the cancer. Compositions are available that overcome these immunosuppressive factors but they produce toxic side-effects which can be life-threatening. There is thus a need for efficacious compositions and methods with reduced toxicity. In collaboration with the laboratory of Alan Epstein (Keck School of Medicine) candidate compositions and methods have been generated and more are under development. Patents covering some compositions and methods have issued and additional patent applications are ongoing and planned. For additional information see
Cancer Immunotherapy Research:
http://www-hsc.usc.edu/~hrkaslow/Research/cancerimmunotherapy.html
Patents http://www-hsc.usc.edu/~hrkaslow/Research/Patents/

Education Efforts:
Dr. Kaslow’s graduate (UCSD) work involved endocrinology and metabolism and his post-doctoral (UCSF) research focused on cell signaling mechanisms. His teaching efforts continue in those areas in graduate, medical, and pharmacy courses. Dr. Kaslow serves as:
Director, MS program in Medical Physiology
Co-chair of the Endocrinology section of the medical student curriculum.
Dr. Kaslow actively participates in the continuing refinement and revision of the medical and graduate student curricula and is developing software for the analysis and management of the curriculum.

Publications

P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol. 2005 Feb 15; 174(4):1971-9. View in: PubMed

Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea. 2002 Mar; 21(2):210-4. View in: PubMed

Effect of anti-inflammatory cytokines on the activation of lymphocytes by lacrimal gland acinar cells in an autologous mixed cell reaction. Adv Exp Med Biol. 2002; 506(Pt B):789-94. View in: PubMed

Autologous lacrimal-lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp Eye Res. 2000 Jul; 71(1):23-31. View in: PubMed

Lacrimal gland epithelial cells stimulate proliferation in autologous lymphocyte preparations. Exp Eye Res. 2000 Jul; 71(1):11-22. View in: PubMed

Sjögren's autoimmunity: how perturbation of recognition in endomembrane traffic may provoke pathological recognition at the cell surface. J Mol Recognit. 1998; 11(1-6):40-8. View in: PubMed

A method to study induction of autoimmunity in vitro: co-culture of lacrimal cells and autologous immune system cells. Adv Exp Med Biol. 1998; 438:583-9. View in: PubMed

Authors and Editors of the world unite. FASEB J. 1995 Feb; 9(2):291. View in: PubMed

Molecular engineering of cholera toxin. Adv Exp Med Biol. 1995; 371B:1513-8. View in: PubMed

Regulation of cytotoxic T cells by ecto-nicotinamide adenine dinucleotide (NAD) correlates with cell surface GPI-anchored/arginine ADP-ribosyltransferase. J Immunol. 1994 Nov 01; 153(9):4048-58. View in: PubMed

Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs. Infect Immun. 1994 Aug; 62(8):3051-7. View in: PubMed

Recombinant microbial ADP-ribosylating toxins of Bordetella pertussis, Vibrio cholerae, and enterotoxigenic Escherichia coli: structure, function, and toxoid vaccine development. Bioprocess Technol. 1994; 19:185-203. View in: PubMed

CTX-B inhibits CTL cytotoxicity and cytoskeletal movements. Immunopharmacology. 1993 Sep-Oct; 26(2):93-104. View in: PubMed

Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum. J Clin Microbiol. 1992 Jun; 30(6):1380-7. View in: PubMed

Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J. 1992 Jun; 6(9):2684-90. View in: PubMed

Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect Immun. 1991 Nov; 59(11):4266-70. View in: PubMed

Evaluation of antibodies elicited by immunization with pertussis toxin. Dev Biol Stand. 1991; 73:143-50. View in: PubMed

The molecular engineering of pertussis toxoid. Dev Biol Stand. 1991; 73:75-8. View in: PubMed

Monoclonal antibodies against the enzymatic subunit of both pertussis and cholera toxins. Dev Biol Stand. 1991; 73:133-41. View in: PubMed

Monoclonal antibodies that inhibit ADP-ribosyltransferase but not NAD-glycohydrolase activity of pertussis toxin. Infect Immun. 1990 Mar; 58(3):746-52. View in: PubMed

Radiometric assays for glycerol, glucose, and glycogen. Anal Biochem. 1989 Jul; 180(1):11-6. View in: PubMed

Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin. J Biol Chem. 1989 Apr 15; 264(11):6386-90. View in: PubMed

Developments toward a recombinant pertussis vaccine. Adv Exp Med Biol. 1989; 251:1-7. View in: PubMed

Regulation of glycogen synthase in muscle and adipose tissue during fasting and refeeding. Am J Physiol. 1988 Jun; 254(6 Pt 1):E720-5. View in: PubMed

Fructose effect to suppress hepatic glycogen degradation. J Biol Chem. 1987 Aug 25; 262(24):11470-7. View in: PubMed

Sulfhydryl-alkylating reagents inactivate the NAD glycohydrolase activity of pertussis toxin. Biochemistry. 1987 Jul 14; 26(14):4397-402. View in: PubMed

Structure-activity analysis of the activation of pertussis toxin. Biochemistry. 1987 Jan 13; 26(1):123-7. View in: PubMed

Stimulation of the thiol-dependent ADP-ribosyltransferase and NAD glycohydrolase activities of Bordetella pertussis toxin by adenine nucleotides, phospholipids, and detergents. Biochemistry. 1986 May 06; 25(9):2720-5. View in: PubMed

L-type glycogen synthase. Tissue distribution and electrophoretic mobility. J Biol Chem. 1985 Aug 25; 260(18):9953-6. View in: PubMed

Adenine nucleotides directly stimulate pertussis toxin. J Biol Chem. 1985 Mar 10; 260(5):2585-8. View in: PubMed

Fasting and diabetes alter adipose tissue glycogen synthase. Am J Physiol. 1984 Nov; 247(5 Pt 1):E581-4. View in: PubMed

Isozymes of glycogen synthase. FEBS Lett. 1984 Jul 09; 172(2):294-8. View in: PubMed

Genetic analysis of cyclic nucleotide phosphodiesterases in S49 mouse lymphoma cells. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16:185-94. View in: PubMed

A direct radioassay for pyruvate kinase activity. Anal Biochem. 1983 Oct 15; 134(2):495-8. View in: PubMed

Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell. J Biol Chem. 1983 Aug 25; 258(16):9717-23. View in: PubMed

Cholera toxin can catalyze ADP-ribosylation of cytoskeletal proteins. J Cell Biol. 1981 Nov; 91(2 Pt 1):410-3. View in: PubMed

Fibroblast defect in pseudohypoparathyroidism, type I: reduced activity of receptor-cyclase coupling protein. J Clin Endocrinol Metab. 1981 Sep; 53(3):636-40. View in: PubMed

Hormone-sensitive adenylate cyclase. Mutant phenotype with normally regulated beta-adrenergic receptors uncoupled with catalytic adenylate cyclase. Mol Pharmacol. 1981 Sep; 20(2):435-41. View in: PubMed

An Mr = 52,000 peptide can mediate effects on cholera toxin on adenylate cyclase in intact cells. Mol Pharmacol. 1981 May; 19(3):406-10. View in: PubMed

Human mutation affecting hormone-sensitive adenylate cyclase. Prog Clin Biol Res. 1981; 63:433-7. View in: PubMed

Apparent phosphorylation of glycogen synthase in mammalian cells lacking cyclic AMP-dependent protein kinase. FEBS Lett. 1980 Aug 11; 117(1):219-23. View in: PubMed

Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med. 1980 Jul 31; 303(5):237-42. View in: PubMed

A regulatory component of adenylate cyclase from human erythrocyte membranes. J Biol Chem. 1980 Apr 25; 255(8):3736-41. View in: PubMed

Genetic analysis of hormone-sensitive adenylate cyclase. Adv Cyclic Nucleotide Res. 1980; 13:1-37. View in: PubMed

A regulatory component of adenylate cyclase is located on the inner surface of human erythrocyte membranes. Biochem Biophys Res Commun. 1979 Oct 29; 90(4):1237-41. View in: PubMed

Adaptations of glycogen metabolism in rat epididymal adipose tissue during fasting and refeeding. J Biol Chem. 1979 Jun 10; 254(11):4678-83. View in: PubMed

Interconversion between multiple glucose 6-phosphate-dependent forms of glycogen synthase in intact adipose tissue. J Biol Chem. 1979 Jun 10; 254(11):4674-7. View in: PubMed

Adenylate cyclase assembled in vitro: cholera toxin substrates determine different patterns of regulation by isoproterenol and guanosine 5'-triphosphate. Mol Pharmacol. 1979 May; 15(3):472-83. View in: PubMed

Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase. J Biol Chem. 1978 Oct 25; 253(20):7120-3. View in: PubMed

Reconstitution of cholera toxin-activated adenylate cyclase. Proc Natl Acad Sci U S A. 1978 Jul; 75(7):3113-7. View in: PubMed

Purification of the cAMP receptor protein by affinity chromatography. Biochem Biophys Res Commun. 1974 Jul 24; 59(2):813-21. View in: PubMed

Powered bySC CTSI